Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting

    SHENZHEN, China, July 17 /Xinhua-EMWNews/ -- Mindray

Medical International Limited (NYSE: MR), a leading developer, manufacturer

and marketer of medical devices worldwide has announced today that it will

highlight all of its marketed in-vitro diagnostic products as well as

unveil three new units and reagents at the 2008 Annual American Association

for Clinical Chemistry (AACC) conference. The conference will be attended

by Mr. Jie Liu, Executive Vice President of International Sales & Marketing

and Mr. Wei Wang, Vice President of Research and Development.



    Mindray will showcase its entire line of in-vitro diagnostic products

at the conference, along with three demo units: the BC-5300 and BC-5380,

both of which are Hematology Analyzers, the BA-88A, a Semi-automatic

Biochemistry Analyzer, and the first five reagents for the Biochemistry

Analyzer. All products are expected to enter the international market in

the second half of 2008.



    "Mindray's presence at this conference speaks volumes about the

direction in which the company is heading," commented Mr. Li Xiting,

Mindray's President and Co-Chief Executive Officer. "Presenting at the AACC

conference allows us to showcase our high quality products, and demonstrate

their efficacy to the medical community."



    Mindray's products will be on display at AACC booth 825 in Hall A. The

60th Annual AACC conference will take place from July 29 through July 31 at

the Washington Convention Center in Washington D.C. AACC is an

international society comprised of medical professionals with an interest

in clinical chemistry, clinical laboratory science, and laboratory

medicine. Founded in 1948, the society has over 9,000 members and is

headquartered in Washington, D.C.

    About Mindray



    Mindray is a leading developer, manufacturer and marketer of medical

devices worldwide. Established in 1991, Mindray offers a broad range of

products across three primary business segments: patient monitoring & life

support products, in-vitro diagnostic products and medical imaging systems.

Mindray is globally headquartered in Shenzhen, China, with U.S.

headquarters in Mahwah, New Jersey. Mindray also has another 12

international sales and service offices in Amsterdam, Frankfurt, Istanbul,

London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and

Vancouver.



    For more information, please visit http://www.mindray.com .



    Safe Harbor Statement



    This announcement contains forward-looking statements. These statements

are made under the "safe harbor" provisions of the U.S. Private Securities

Litigation Reform Act of 1995. These forward-looking statements can be

identified by terminology such as "will," "expects," "anticipates,"

"future," "intends," "plans," "believes," "estimates," "confident" and

similar statements. Statements that are not historical facts, including

statements about Mindray's beliefs and expectations, are forward-looking

statements. Forward-looking statements involve inherent risks and

uncertainties. Information regarding these risks and uncertainties is

included in our public filings with the Securities and Exchange Commission.

All information provided in this press release is as of July 17, 2008, and

Mindray undertakes no duty to update such information, except as required

under applicable law.






    For investor and media inquiries, please contact:



    In the U.S:

     Evan Smith,

     FD

     Tel:   +1-212-850-5606

     Email: [email protected]



     John Capodanno,

     FD

     Tel:   +1-212-850-5705

     Email: [email protected]



    In China:

     Susan Du

     Mindray Medical International Limited

     Tel:   +86-755-2658-2518

     Email: [email protected]